Document text
Principal Investigator: John Mascola
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $393,065
Funding agency: National Institute of Allergy and Infectious Diseases
During the past years, the Virology Laboratory has collaborated with other intramural NIAID labs and other external collaborators to develop a pseudovirus neutralization assay and an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). For the neutralization assay, we have provided technical and software assistance to other VRC labs, and developed a shared Standard Operating Procedure. Since more SARS-CoV-2 variant viruses continuously arise in the world, we are continuously making various pseudoviruses corresponding to the emerging variant viruses. And more importantly, the pseudovirus neutralization assay also needed to be modified to adapted to the new variant viruses for the assay appropriate usage. The assay is being used by laboratory staff to evaluate human serum samples from individuals recovering from COVID-19 and from volunteers in the clinical trial of the Moderna mRNA1273 vaccine. We are also isolating and characterizing monoclonal antibodies from individuals recovering from COVID-19 disease, assessing for SARS-CoV-2 neutralizing antibodies, which are valuable research reagents with great potential for therapeutic and prevention purposes against the continuously emerging SARS-CoV-2 variants.
For the mRNA vaccine, we show that mRNA-1273 induces potent neutralizing antibody responses to the initial strain and variant SARS-CoV-2, as well as high T cells responses. Importantly, this mRNA vaccine in the clinical trial have shown a robust neutralizing response to SARS-CoV-2. We are testing various new designs of non-infectious self-assembly Virus-Like-Particle (VLP) expressing the SARS-CoV-2 spike on the particles' surface as a potential vaccine which may elicit better antibodies. Since the mRNA vaccine has proved to be a highly successful vaccine platform, we will continue to develop the VLP vaccine candidates in genetic (mRNA or DNA) platform.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Animals><Antibodies><Antibody Response><Assay><Bioassay><Biologic Assays><Biological Assay><Blood Serum><COVID-19><COVID-19 infection><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 infection><COVID19 virus><CV-19><CV19><Clinical><Clinical Treatment Moab><Clinical Trials><CoV-2><CoV2><Computer software><DNA><Deoxyribonucleic Acid><Development><Disease><Disorder><ELISA><Enzyme-Linked Immunosorbent Assay><Genetic><Human><Immunize><Individual><Laboratories><Messenger RNA><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Prevention><Procedures><RNA vaccine><RNA-based vaccine><Reagent><Research><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Software><Standardization><Surface><T cell response><Testing><Therapeutic><Vaccinated><Vaccines><Variant><Variation><Virus><Virus-like particle><Wuhan coronavirus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><design><designing><developmental><evaluate vaccines><hCoV19><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><mAbs><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><nCoV2><neutralizing antibody><particle><pre-clinical><preclinical><response><self assembly><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><vaccine antibodies><vaccine candidate><vaccine evaluation><vaccine induced antibodies><vaccine screening><vaccine testing><vaccine-induced antibodies><virology><virus-like nanoparticles><viruslike particle><volunteer>